Dysfunctional dystrophin, the muscle protein affected in Duchenne, leads to an important choice for patients about how to ...

Ifetroban improved heart function and reduced cardiac damage biomarkers in people with DMD in a Phase 2 clinical trial.

Absent a federal committee’s recommendation, Duchenne muscular dystrophy advocates are trying to get states to adopt ...

A recent study involving researchers from the University of Basel reveals that slowing down the intracellular transport of ...

Family fears losing Medicaid coverage, which they rely on for life-saving care. They face uncertainty due to new work ...

Shares of Dyne Therapeutics declined after the company commenced an underwritten public offering and said it had secured up to $275 million of debt financing. The stock fell 9.8% to $8.59 on Monday.

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it ...

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced it has ...

A recent study involving researchers from the University of Basel reveals that slowing down the intracellular transport of ...

"It also reminds you of how good people are and how good the world is. The support and the love that we've received, I can't ...

New consensus guidelines outline best practices for orthopedic management in Duchenne muscular dystrophy, focusing on ...